Myotonic Dystrophy 1Phase 2NCT02858908
Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy
A Phase 2 study testing Tideglusib in people with Myotonic Dystrophy 1, run by AMO Pharma Limited at 1 site in United Kingdom.
Trial summary
The purpose of this study is to determine whether Tideglusib is safe and efficacious in the treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy. The pharmacokinetics of tideglusib and its primary metabolite will also be investigated. Read more about this study
- Who is it for?
- Ages 12 to 45 years
- Conditions the study is for
- Myotonic Dystrophy 1
- What is being tested?
- Tideglusib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 20 Jul 2016to Jan 2018
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 45 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Adolescents or adults with diagnosis of congenital or juvenile-onset type 1 myotonic dystrophy (DM-1)
- Diagnosis must be genetically confirmed
- Subjects must be male or female aged 12 years to 45 years
- Subjects must have a Clinical Global Impression - Severity (CGI-S) score of 4 or greater at Screening and Run-in (V2)
- Subjects must be ambulatory and able to complete the 10 metre walk/run test (splints allowed)
- Subject's legally authorized representative (LAR) must provide written informed consent and there must be written consent or assent (as age applicable and developmentally appropriate) by the subject before any study-related procedures are conducted
Who cannot join
- Non-ambulatory (full time) wheel chair user
- Receiving stimulant medication
- Receiving other medications/therapies not stable (changed) within 4 weeks prior to Run-in (V2)
- Medical illness or other concern which would cause investigator to conclude subjects will not be able to perform the study procedures or assessments or would confound interpretation of data obtained during assessment.
- Current enrolment in a clinical trial of an investigational drug or enrolment in a clinical trial of an investigational drug in the last 6 months
- Women of child bearing potential who are pregnant, lactating or not willing to use a protocol defined acceptable contraception method if sexually active and not surgically sterile.
Show all 12Show fewer
- Gastrointestinal disease which may interfere with the absorption, distribution, metabolism or excretion of the study medication and impact the interpretability of the study results
- Current clinically significant (as determined by the investigator) cardiovascular, renal, hepatic, endocrine or respiratory disease
- Clinically significant heart disease (in the opinion of the investigator) or second or third degree heart block, atrial flutter, atrial fibrillation, ventricular arrhythmias, or is receiving medication for treatment of a cardiac arrhythmia
- A history of chronic liver disease with current out of range values for Alanine transaminase (ALT), clinically relevant hepatic steatosis or other clinical manifestations of ongoing liver disease
- A history of significant drug allergy (such as Steven-Johnson syndrome, anaphylaxis)
- A history of alcohol or substance use disorders
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Newcastle-upon-Tyne Hospitals NHS Trust
Newcastle upon Tyne, Tyne and Wear, NE1 4LP
About this study
Official title: A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400mg Or 1000mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy
The purpose of this study is to determine whether Tideglusib is safe and efficacious in the treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy. The pharmacokinetics of tideglusib and its primary metabolite will also be investigated.
- Conditions
- Myotonic Dystrophy 1
- Being tested
- Tideglusib
- Medical subject headings
- Myotonic Dystrophy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TideglusibDrug
Tideglusib for oral suspension,
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1 - Tideglusib | Experimental | 1000 mg tideglusib, orally, once daily Receives: Drug: Tideglusib |
| Cohort 2 - Tideglusib | Experimental | 400 mg tideglusib, orally, once daily Receives: Drug: Tideglusib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety (Adverse Events)
Incidence of Adverse events (AEs), including serious adverse events (SAEs), between baseline to end of study.
Measured: 12 weeks
Secondary outcomes (19)
Plasma Concentration of Tideglusib
Pharmacokinetic samples were collected to determine Tideglusib plasma concentration
Measured: 12 weeks
Blood Pharmacokinetics of Tideglusib
Pharmacokinetic samples were collected to determine time of the maximum plasma concentration and terminal elimination half-life of tideglusib
Measured: 12 weeks
Area Under the Plasma Concentration vs. Time Curve of Tideglusib
Pharmacokinetic samples were collected to determine area under the plasma concentration vs. time curve from 0 to 12 h and area under the plasma concentration vs. time curve from 0 to 24 h of tideglusib
Measured: 12 weeks
10 Metre Walk/Run Test
The 10-metre walk/run test is a performance measure used to assess walking speed in metres per second over a short distance and was used as an assessment of functional mobility. Time taken to complete the 10m walk/run test at fastest and preferred speed is measured.
Measured: 12 weeks
Computerised Handgrip Myometer Measure of Grip Strength and Muscle Relaxation Time
Handgrip myometry is used as a measure of myotonia and muscle strength for the dominant hand
Measured: 12 weeks
Respiratory Forced Vital Capacity (FVC)
FVC is a measure of lung function (the total amount of air exhaled during a Forced Expiratory Volume is measured using a spirometer)
Measured: 12 weeks
Dual-energy X-ray Absorptiometry (DXA)
DXA utilises two low energy X-ray beams, with different energy levels, which are aimed at the subject's bones. The DXA scan is more typically used to measure bone mineral density, however it can also be used to measure total lean muscle mass
Measured: 12 weeks
Clinical Global Impressions- Severity (CGI-S)
The CGI-S is a 7-point Likert type scale that requires the clinician to rate the severity of the subject's illness at the time of assessment, relative to the clinician's past experience with subjects who have the same diagnosis. Considering total clinical experience, a subject is assessed on severity of illness at the time of rating 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. Change in CGI-S was observed in only 1 subject. Consequently statistical analysis was not conducted.
Measured: 12 weeks
Clinical Global Impressions- Improvement (CGI-I)
The CGI-I requires the clinician to rate how much the subject's illness has improved or worsened relative to a baseline state.
A seven point Likert type scale is used from 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.
Measured: 12 weeks
Actigraphy (3-minute Bouts of Activity)
Actigraphy is a non-invasive method of monitoring physical activity via an actigraph device. The actigraph device was worn on the waist during waking hours, according to the device's instruction manual.
Measured: 12 weeks
Actigraphy (>10-minute Bouts of Activity)
Actigraphy is a non-invasive method of monitoring physical activity via an actigraph device. The actigraph device was worn on the waist during waking hours, according to the device's instruction manual.
Measured: 12 weeks
Actigraphy (Steps)
Actigraphy is a non-invasive method of monitoring physical activity via an actigraph device. The actigraph device was worn on the waist during waking hours, according to the device's instruction manual.
Measured: 12 weeks
Nine Hole Peg Test (NHPT)
Measure of fine manual dexterity. Time to taken to complete the NHPT (dominant hand) is recorded.
Measured: 12 weeks
Top 3 Concerns Visual Analogue Scale (VAS) Score
The Top 3 concerns VAS allows caregivers to identify their main three causes of concern, related to the subject's myotonic dystrophy, rather than these being pre-specified within a scale and then rating how these concerns have changed at specific time-points during the study. Subjects, where possible, and caregivers were asked to rate three causes for concern by drawing a vertical mark on a 10 cm long visual analogue scale with anchors of "not at all severe" at the left end (0 cm) and "very severe" at the right end (10 cm). A score for each concern was to be determined by measuring the number of centimeters on the 10 cm VAS line from the anchor point on the left side of the line. A total VAS score for each subject was calculated as the sum of the scores for the 3 concerns (minimum = 0 cm, maximum = 30 cm). A higher score represents a worse outcome.
Measured: 12 weeks
Ohio State University (OSU) Autism Rating Scale (OARS)
The OARS-4 contains the autism signs and symptoms in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. These were to be rated with the degree of impairment the subject experiences for the given symptom. The symptoms were to be elicited in a semi-structured interview with the subject's primary caregiver. The assessor was to take both frequency/duration and degree of impairment into account and how much the item interferes with relationships, learning, and/or activities of daily living. The scores for this assessment were from 0 (Never or Rarely; Not a Problem) to 3 (Very Often; A Severe Problem): a score for each symptom of social impairment, communication impairment and restricted patterns were averaged to provide a total impairment score. A higher score represents a worse outcome (minimum = 0, maximum 3).
Measured: 12 weeks
Ohio State University (OSU) Autism Clinical Global Impression (CGI)
The OSU Autism CGI scale contains separate subscales for symptom severity and for global improvement. These are rated in a similar way to the National Institute of Mental Health (NIMH) CGI Severity scale, but it is focused on autism spectrum symptoms. OSU Autism CGI-severity and OSU Autism CGI-improvement scores use a seven point Likert rating scale from 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.
Measured: 12 weeks
Clinician-completed Domain Specific Cause for Concern Visual Analogue Scale (VAS): Myotonic Dystrophy
The Clinician-completed Domain Specific Causes for Concern is a Visual Analogue Scale completed by the clinician that scores the severity of concerns of domains that are clinically relevant in myotonic dystrophy. The severity of the clinician's concern is scored by using a 10 cm visual analogue scale (VAS), with anchors of "not at all severe" at the left end (0 cm) and "very severe" at the right end (10 cm). The clinician is asked to make a vertical line indicating his/her level of concern in each domain, using a time frame of the past week for reference. A score is to be determined by measuring the number of centimeters on the 10 cm VAS line from the anchor point on the left side of the line. A total VAS score for each subject was calculated as the sum of the scores for the 17 domains (minimum = 0, maximum = 170 cm). A higher score represents a worse outcome.
Measured: 12 weeks
Peabody Picture Vocabulary Test (PPVT)
The PPVT-4 scale is a norm-referenced instrument for measuring the receptive (hearing) vocabulary of children and adults. It contains training items and 228 test items, each consisting of four full-colour pictures as response options on a page. For each item, the examiner says a word, and the examinee responds by selecting the picture that best illustrates that word's meaning. Each administration of the test produces a raw score (number of test items answered correctly), which can be converted to a standard score (using age-based norms) with a mean of 100 and a standard deviation of 15. Higher scores mean a better performance/receptive vocabulary.
Measured: 12 weeks
Biomarker - Lymphocyte GSK3β Levels and Activity
Total levels of GSK3β protein was determined via x-MAP technology in a Luminex 200 platform using the AKT Pathway Total Multispecies 7-Plex Panel from ThermoFisher Scientific.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Aug 2016 (estimated)
- Study start20 Jul 2016
- Primary completionJan 2018
- Study completionJan 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Myotonic Dystrophy 1Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- AMO Pharma Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Grainne Gorman, MB BCh BAO LRCP&SI MRCP FRCP, Principal investigator, Institute of Neuroscience, Newcastle University.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02858908
- Sponsor's protocol ID
- AMO-02-MD-2-001
- Other IDs
- 2016-000067-16, 2016
- Status last verified
- Aug 2025
- First submitted
- 4 Aug 2016
- Last updated
- 11 Sep 2025
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Expanded access
- Available
Publications
Horrigan J, Gomes TB, Snape M, Nikolenko N, McMorn A, Evans S, Yaroshinsky A, Della Pasqua O, Oosterholt S, Lochmuller H. A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1). Pediatr Neurol. 2020 Nov;112:84-93. doi: 10.1016/j.pediatrneurol.2020.08.001. Epub 2020 Aug 5.
PubMed 32942085
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400mg Or 1000mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy
- ClinicalTrials.gov ID
- NCT02858908
- Acronym / sponsor ID
- AMO-02-MD-2-001
- Conditions
- Myotonic Dystrophy 1
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- AMO Pharma LimitedIndustry (pharma, biotech, devices)
- Study start
- 20 Jul 2016 (actual)
- Primary completion
- Jan 2018 (actual)
- Study completion
- Jan 2018 (actual)
- First posted
- 8 Aug 2016 (estimated)
- Results
- Posted 11 Sep 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether Tideglusib is safe and efficacious in the treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy. The pharmacokinetics of tideglusib and its primary metabolite will also be investigated.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cohort 1 - Tideglusib | Experimental | Drug: Tideglusib1000 mg tideglusib, orally, once daily |
| Cohort 2 - Tideglusib | Experimental | Drug: Tideglusib400 mg tideglusib, orally, once daily |
Who may qualify
- Ages
- 12 to 45 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (6 listed)
- Adolescents or adults with diagnosis of congenital or juvenile-onset type 1 myotonic dystrophy (DM-1)
- Diagnosis must be genetically confirmed
- Subjects must be male or female aged 12 years to 45 years
- Subjects must have a Clinical Global Impression - Severity (CGI-S) score of 4 or greater at Screening and Run-in (V2)
- Subjects must be ambulatory and able to complete the 10 metre walk/run test (splints allowed)
Key exclusion criteria (12 listed)
- Non-ambulatory (full time) wheel chair user
- Receiving stimulant medication
- Receiving other medications/therapies not stable (changed) within 4 weeks prior to Run-in (V2)
- Medical illness or other concern which would cause investigator to conclude subjects will not be able to perform the study procedures or assessments or would confound interpretation of data obtained during assessment.
- Current enrolment in a clinical trial of an investigational drug or enrolment in a clinical trial of an investigational drug in the last 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TideglusibTideglusib for oral suspension, | Drug | Cohort 1 - Tideglusib, Cohort 2 - Tideglusib |
Primary outcome
Safety (Adverse Events)
Time frame: 12 weeks
Incidence of Adverse events (AEs), including serious adverse events (SAEs), between baseline to end of study.
19 secondary outcomes
Plasma Concentration of Tideglusib
Time frame: 12 weeks
Blood Pharmacokinetics of Tideglusib
Time frame: 12 weeks
Area Under the Plasma Concentration vs. Time Curve of Tideglusib
Time frame: 12 weeks
10 Metre Walk/Run Test
Time frame: 12 weeks
Computerised Handgrip Myometer Measure of Grip Strength and Muscle Relaxation Time
Time frame: 12 weeks
Respiratory Forced Vital Capacity (FVC)
Time frame: 12 weeks
Dual-energy X-ray Absorptiometry (DXA)
Time frame: 12 weeks
Clinical Global Impressions- Severity (CGI-S)
Time frame: 12 weeks
Clinical Global Impressions- Improvement (CGI-I)
Time frame: 12 weeks
Actigraphy (3-minute Bouts of Activity)
Time frame: 12 weeks
Actigraphy (>10-minute Bouts of Activity)
Time frame: 12 weeks
Actigraphy (Steps)
Time frame: 12 weeks
Nine Hole Peg Test (NHPT)
Time frame: 12 weeks
Top 3 Concerns Visual Analogue Scale (VAS) Score
Time frame: 12 weeks
Ohio State University (OSU) Autism Rating Scale (OARS)
Time frame: 12 weeks
Ohio State University (OSU) Autism Clinical Global Impression (CGI)
Time frame: 12 weeks
Clinician-completed Domain Specific Cause for Concern Visual Analogue Scale (VAS): Myotonic Dystrophy
Time frame: 12 weeks
Peabody Picture Vocabulary Test (PPVT)
Time frame: 12 weeks
Biomarker - Lymphocyte GSK3β Levels and Activity
Time frame: 12 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 32942085Horrigan J, Gomes TB, Snape M, Nikolenko N, McMorn A, Evans S, Yaroshinsky A, Della Pasqua O, Oosterholt S, Lochmuller H. A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1). Pediatr Neurol. 2020 Nov;112:84-93. doi: 10.1016/j.pediatrneurol.2020.08.001. Epub 2020 Aug 5.
Related trials for Myotonic Dystrophy 1
RecruitingPhase 3
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
Myotonic Dystrophy Type 1 (DM1), DM1
RecruitingObservational study
DMCRN-02-001: Assessing Pediatric Endpoints in DM1
Congenital Myotonic Dystrophy, CDM
RecruitingObservational study
Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Myotonic Dystrophy 1, DM1
RecruitingObservational study
The Spanish National Registry for Myotonic Dystrophy Type 1
Myotonic Dystrophy 1, DM1
RecruitingObservational study
Metabolomic Biomarkers of Myotonic Dystrophy
Myotonic Dystrophy Type 1
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Grainne Gorman, MB BCh BAO LRCP&SI MRCP FRCP principal investigator
Institute of Neuroscience, Newcastle University.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Tideglusib in people with Myotonic Dystrophy 1, run by AMO Pharma Limited at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 11 Sep 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety (Adverse Events) (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02858908, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2025.